Volunteer for research to improve the health of moms and babies.
MotherToBaby is currently enrolling pregnant women in a study examining the use of Dupixent® (dupilumab) to treat moderate-to-severe eczema (atopic dermatitis) or asthma during pregnancy. The study is conducted through phone interviews—no changes to your normal routine or travel required. If you’ve taken Dupixent® (dupilumab) and are pregnant, you may qualify for this important study.
“There is a huge need to generate more data for all of the drugs that pregnant women need to take.”— Christina Chambers, PhD, MPH, MotherToBaby Pregnancy Studies
MotherToBaby is the most trusted information source for medication safety in pregnancy. Make an impact on maternal health by enrolling into our pregnancy study.
Join our Dupixent® Study
Your information is confidential.
MotherToBaby Pregnancy Studies are conducted by the Organization of Teratology Information Specialists (OTIS) and coordinated by the University of California San Diego. MotherToBaby is listed as a resource for information about medications in pregnancy by the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC).